ATAI Life Sciences launches EmpathBio to treat post-traumatic stress disorder with novel MDMA product

November 8, 2020 Articles 7:21 pm

Today, ATAI Life Sciences, a global biotech developing psychedelic and non-psychedelic compounds for various mental health indications, announced the launch of EmpathBio, a wholly-owned subsidiary developing derivatives of  3,4-methylenedioxy-methamphetamine (MDMA) for the treatment of post-traumatic stress disorder (PTSD) and other indications.

JOIN THE ATAI #INSIGHTNETWORK

Receive the latest news on atai and innovations in the space.

Email
submit